- Home
- TSHA vs XPRO Comparison
TSHA vs XPRO Comparison
Compare TSHA & XPRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- XPRO
- Stock Information
- Founded
- TSHA 2019
- XPRO 1938
- Country
- TSHA United States
- XPRO United States
- Employees
- TSHA N/A
- XPRO N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- XPRO Oilfield Services/Equipment
- Sector
- TSHA Health Care
- XPRO Energy
- Exchange
- TSHA Nasdaq
- XPRO Nasdaq
- Market Cap
- TSHA 1.4B
- XPRO 1.5B
- IPO Year
- TSHA 2020
- XPRO 2013
- Fundamental
- Price
- TSHA $3.84
- XPRO $12.92
- Analyst Decision
- TSHA Strong Buy
- XPRO Buy
- Analyst Count
- TSHA 9
- XPRO 4
- Target Price
- TSHA $10.22
- XPRO $14.00
- AVG Volume (30 Days)
- TSHA 4.1M
- XPRO 1.1M
- Earning Date
- TSHA 11-04-2025
- XPRO 10-23-2025
- Dividend Yield
- TSHA N/A
- XPRO N/A
- EPS Growth
- TSHA N/A
- XPRO 313.92
- EPS
- TSHA N/A
- XPRO 0.59
- Revenue
- TSHA $6,310,000.00
- XPRO $1,661,811,000.00
- Revenue This Year
- TSHA N/A
- XPRO N/A
- Revenue Next Year
- TSHA N/A
- XPRO $2.88
- P/E Ratio
- TSHA N/A
- XPRO $21.78
- Revenue Growth
- TSHA N/A
- XPRO N/A
- 52 Week Low
- TSHA $1.05
- XPRO $6.70
- 52 Week High
- TSHA $5.51
- XPRO $14.97
- Technical
- Relative Strength Index (RSI)
- TSHA 37.78
- XPRO 46.84
- Support Level
- TSHA $3.89
- XPRO $13.39
- Resistance Level
- TSHA $4.55
- XPRO $14.08
- Average True Range (ATR)
- TSHA 0.39
- XPRO 0.61
- MACD
- TSHA -0.19
- XPRO -0.10
- Stochastic Oscillator
- TSHA 8.99
- XPRO 20.25
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About XPRO Expro Group Holdings N.V.
Expro Group Holdings NV offers products and services that span the well life cycle, including well construction, well flow management, well intervention and integrity, and subsea well access. It maintains operations around the world and specializes in offshore production solutions. It also provides production optimization for both onshore and offshore applications. The company has four operating segments: North and Latin America (NLA); Europe and Sub-Saharan Africa (ESSA); Middle East and North Africa (MENA), and Asia-Pacific (APAC). The majority of its revenue is derived from North and Latin America (NLA) segment.